UBS Maintains Buy on Tenet Healthcare, Lowers Price Target to $94
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Andrew Mok maintains a Buy rating on Tenet Healthcare (NYSE:THC) but lowers the price target from $104 to $94.
November 01, 2023 | 7:14 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
UBS analyst maintains a Buy rating on Tenet Healthcare but lowers the price target from $104 to $94.
The news is directly related to Tenet Healthcare (THC). The maintained Buy rating indicates a positive outlook for the company, however, the lowered price target may indicate a slower growth expectation. This could have a neutral impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100